(Total Views: 730)
Posted On: 08/13/2025 10:02:02 PM
Post# of 155780
I believe you are right , LL is not PD-L1 therapy , check point inhibitors are .
Seems LL may elevate in some patients / cancers PD-L1 so check point inhibitors will be working even better .
And this is extremely important function !! But we need check point inhibitors to block these receptors , PD-L1.
Malignant Melanoma is high on the cancer list for LL , as it is strong in expressing CCR5 , and most probably results will be even better when to LL we will add check point inhibitor ..., but in this article IMO , nothing suggest LL was used in this patient as PD-L1 therapy ...but check point inhibitor was.. .
Again , IMO..
Seems LL may elevate in some patients / cancers PD-L1 so check point inhibitors will be working even better .
And this is extremely important function !! But we need check point inhibitors to block these receptors , PD-L1.
Malignant Melanoma is high on the cancer list for LL , as it is strong in expressing CCR5 , and most probably results will be even better when to LL we will add check point inhibitor ..., but in this article IMO , nothing suggest LL was used in this patient as PD-L1 therapy ...but check point inhibitor was.. .
Again , IMO..
(10)
(0)
